Zkusit zdarma
Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc.

ARQT
Cena:
$ 20.86
-0.15 (-0.71%)
Valuace
70
Růst
53
Zdraví
75
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
Arcutis Biotherapeutics: The Dermatology Platform Is Starting To Compound

Arcutis Biotherapeutics: The Dermatology Platform Is Starting To Compound

7:54 15-05-2026

Arcutis Biotherapeutics (ARQT) is evolving into a specialized dermatology platform, leveraging ZORYV...

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

16:00 08-05-2026

WESTLAKE VILLAGE, Calif. , May 08, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: A...

Arcutis Biotherapeutics, Inc. (ARQT) Q1 2026 Earnings Call Transcript

Arcutis Biotherapeutics, Inc. (ARQT) Q1 2026 Earnings Call Transcript

0:41 07-05-2026

Arcutis Biotherapeutics, Inc. (ARQT) Q1 2026 Earnings Call Transcript...

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Beats Revenue Estimates

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Beats Revenue Estimates

18:25 06-05-2026

Arcutis Biotherapeutics, Inc. (ARQT) came out with a quarterly loss of $0.09 per share versus the Za...

Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update

Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update

16:00 06-05-2026

Q1 2026 net product revenue for ZORYVE® (roflumilast) was $105.4 million, a 65% increase compared t...

Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know

Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know

11:01 29-04-2026

Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for ...

Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months

Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months

8:00 27-04-2026

Submission supported by data from INTEGUMENT-INFANT Phase 2 open-label study in infants aged 3 month...

Arcutis' ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines

Arcutis' ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines

8:00 22-04-2026

Strong recommendation with high certainty of clinical evidence underscores proven efficacy, safety, ...

Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026

Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026

16:00 15-04-2026

WESTLAKE VILLAGE, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq:...

Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should Know

Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should Know

7:30 08-04-2026

A director of Arcutis Biotherapeutics reported selling 10,000 shares for a total transaction value o...

Arcutis Biotherapeutics, Inc. $ARQT Shares Sold by JPMorgan Chase & Co.

Arcutis Biotherapeutics, Inc. $ARQT Shares Sold by JPMorgan Chase & Co.

4:45 08-04-2026

JPMorgan Chase and Co. decreased its holdings in shares of Arcutis Biotherapeutics, Inc. (NASDAQ: AR...

Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales

Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales

7:30 07-04-2026

Mr. Taylor brings a strong track record launching multiple high-profile therapies, most recently ser...

Phocas Financial Corp. Sells 41,808 Shares of Arcutis Biotherapeutics, Inc. $ARQT

Phocas Financial Corp. Sells 41,808 Shares of Arcutis Biotherapeutics, Inc. $ARQT

6:44 06-04-2026

Phocas Financial Corp. cut its position in Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) by 39.3% in ...

Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference

Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference

16:00 31-03-2026

Arcutis today announced that Arcutis management will present at the 25th Annual Needham Virtual Heal...

Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting

Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting

11:00 28-03-2026

Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consisten...

Ally Bridge Group NY LLC Invests $4.40 Million in Arcutis Biotherapeutics, Inc. $ARQT

Ally Bridge Group NY LLC Invests $4.40 Million in Arcutis Biotherapeutics, Inc. $ARQT

3:31 15-03-2026

Ally Bridge Group NY LLC bought a new position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ: A...

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology

9:00 10-03-2026

ZORYVE cream 0.05% was safe and well-tolerated, with efficacy that was maintained and improved over ...

Intech Investment Management LLC Sells 35,672 Shares of Arcutis Biotherapeutics, Inc. $ARQT

Intech Investment Management LLC Sells 35,672 Shares of Arcutis Biotherapeutics, Inc. $ARQT

5:01 09-03-2026

Intech Investment Management LLC decreased its holdings in shares of Arcutis Biotherapeutics, Inc. (...

Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth

Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth

9:00 05-03-2026

WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq...

Arcutis After The Double: Hypergrowth Peaks, Compounding Remains

Arcutis After The Double: Hypergrowth Peaks, Compounding Remains

9:14 20-02-2026

Arcutis Biotherapeutics shifts to Hold after a 100% rally, as much of the initial de-risked growth t...

close

ARCUTIS BIOTHERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

05-02-2026
WESTLAKE VILLAGE, CALIF., FEB. 05, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC.  (NASDAQ:...
Více zde

ARCUTIS ANNOUNCES POSITIVE TOPLINE RESULTS FOR INTEGUMENT-INFANT PHASE 2 TRIAL OF ZORYVE® (ROFLUMILAST) CREAM 0.05% IN INFANTS WITH MILD TO MODERATE ATOPIC DERMATITIS

02-02-2026
WESTLAKE VILLAGE, CALIF., FEB. 02, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC.  (NASDAQ:...
Více zde

ARCUTIS BIOTHERAPEUTICS, INC. ANNOUNCES TERMINATION OF PROMOTION AGREEMENT WITH KOWA

26-01-2026
WESTLAKE VILLAGE, CALIF., JAN. 26, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC.  (NASDAQ:...
Více zde

ARCUTIS TO REPORT FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PRESENT AT UPCOMING INVESTOR CONFERENCE

22-01-2026
WESTLAKE VILLAGE, CALIF., JAN. 22, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ...
Více zde

NATIONWIDE SURVEY UNDERSCORES CONCERNS WITH USE OF TOPICAL STEROIDS AND NEED FOR LONG-TERM TREATMENT STRATEGIES FACING THE 46 MILLION AMERICANS WITH CHRONIC INFLAMMATORY SKIN CONDITIONS

21-01-2026
NEARLY 9 IN 10 ADULTS AND PARENTS OF CHILDREN WITH PLAQUE PSORIASIS, ATOPIC DERMATITIS, AND SEBORRHE...
Více zde

ARCUTIS HIGHLIGHTS 2026 STRATEGIC PRIORITIES AND ANTICIPATED MILESTONES

12-01-2026
CONTINUED STRONG GROWTH OF ZORYVE® (ROFLUMILAST) IN 2026 WITH FULL-YEAR NET PRODUCT SALES GUIDANCE ...
Více zde

ARCUTIS STRENGTHENS BOARD OF DIRECTORS WITH NEW APPOINTMENT OF AMIT MUNSHI AND HONORS RETIREMENT OF BHASKAR CHAUDHURI

08-12-2025
ARCUTIS TODAY ANNOUNCED THAT AMIT MUNSHI HAS BEEN APPOINTED TO ITS BOD, AND ANNOUNCED THE RETIREMENT...
Více zde

FDA ACCEPTS SUPPLEMENTAL NEW DRUG APPLICATION FOR ARCUTIS' ZORYVE® (ROFLUMILAST) CREAM 0.3% FOR THE TREATMENT OF PLAQUE PSORIASIS IN CHILDREN AGES 2 TO 5

17-11-2025
FDA ACCEPTS SUPPLEMENTAL NEW DRUG APPLICATION FOR ARCUTIS' ZORYVE® (ROFLUMILAST) CREAM 0.3% FOR THE...
Více zde

ARCUTIS COMPLETES ENROLLMENT IN INTEGUMENT-INFANT PHASE 2 STUDY EVALUATING ZORYVE® (ROFLUMILAST) CREAM 0.05% IN INFANTS WITH ATOPIC DERMATITIS

13-11-2025
INVESTIGATIONAL ZORYVE CREAM 0.05% WAS FORMULATED FOR THE DELICATE SKIN OF INFANTS AND YOUNG CHILDRE...
Více zde

ARCUTIS BIOTHERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

07-11-2025
WESTLAKE VILLAGE, CALIF., NOV. 07, 2025 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC.  (NASDAQ:...
Více zde

ARCUTIS ANNOUNCES PUBLICATION OF POSITIVE LONG-TERM SAFETY AND EFFICACY DATA OF ZORYVE® (ROFLUMILAST) FOAM 0.3% IN INDIVIDUALS WITH SEBORRHEIC DERMATITIS IN AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

04-11-2025
ARCUTIS ANNOUNCES PUBLICATION OF POSITIVE LONG-TERM SAFETY AND EFFICACY DATA OF ZORYVE® (ROFLUMILAS...
Více zde

MOTHER-DAUGHTER DUO, TORI SPELLING AND STELLA MCDERMOTT, PARTNER WITH ARCUTIS BIOTHERAPEUTICS IN THE FREE TO BE ME CAMPAIGN, URGING PEOPLE WITH INFLAMMATORY SKIN CONDITIONS TO SPEAK WITH THEIR HEALTHCARE PROVIDER ABOUT LONG-TERM TREATMENTS

30-10-2025
TORI SPELLING SHARES HER AND HER FAMILY'S JOURNEY WITH ECZEMA AND SEBORRHEIC DERMATITIS TO ENCOURAGE...
Více zde

ARCUTIS LAUNCHES ZORYVE® (ROFLUMILAST) CREAM 0.05% FOR THE TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN CHILDREN AGES 2 TO 5

30-10-2025
ONCE-DAILY, EFFECTIVE, SAFE, AND WELL-TOLERATED ZORYVE CREAM 0.05% NOW COMMERCIALLY AVAILABLE FOR CH...
Více zde

ARCUTIS OUTLINES STRATEGY FOR DRIVING SUSTAINABLE GROWTH AND ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS

28-10-2025
Q3 2025 NET PRODUCT REVENUE FOR ZORYVE® (ROFLUMILAST) WAS $99.2 MILLION, A 122% INCREASE COMPARED T...
Více zde

ARCUTIS TO PRESENT AT UPCOMING INVESTOR CONFERENCES

27-10-2025
WESTLAKE VILLAGE, CALIF., OCT. 27, 2025 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ...
Více zde

ARCUTIS TO PRESENT NEW QUALITY OF LIFE AND LONG-TERM DATA WITH ZORYVE® (ROFLUMILAST) CREAM 0.15% AND 0.05% FOR THE TREATMENT OF ATOPIC DERMATITIS AT THE FALL CLINICAL DERMATOLOGY CONFERENCE

24-10-2025
WESTLAKE VILLAGE, CALIF. AND LAS VEGAS, OCT. 24, 2025 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, I...
Více zde

FDA APPROVES ARCUTIS' ZORYVE® (ROFLUMILAST) CREAM 0.05% FOR THE TREATMENT OF ATOPIC DERMATITIS IN CHILDREN AGES 2 TO 5

06-10-2025
ZORYVE CREAM 0.05% PROVIDES RAPID AND EFFECTIVE RELIEF OF MILD TO MODERATE ATOPIC DERMATITIS IN CHIL...
Více zde

ARCUTIS BIOTHERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

03-10-2025
WESTLAKE VILLAGE, CALIF., OCT. 03, 2025 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC.  (NASDAQ:...
Více zde

ARCUTIS BIOTHERAPEUTICS TO HOST VIRTUAL INVESTOR DAY AND REPORT THIRD QUARTER 2025 FINANCIAL RESULTS ON OCTOBER 28, 2025

29-09-2025
WESTLAKE VILLAGE, CALIF., SEPT. 29, 2025 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ...
Více zde

ARCUTIS TO PRESENT MULTIPLE NEW ZORYVE® (ROFLUMILAST) DATA ANALYSES AT EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY CONGRESS

17-09-2025
NEW ANALYSIS OF ZORYVE FOAM 0.3% DEMONSTRATES REDUCTION IN SIGNS AND SYMPTOMS OF SEBORRHEIC DERMATIT...
Více zde

ALLURE MAGAZINE HONORS ARCUTIS' ZORYVE® (ROFLUMILAST) WITH PRESTIGIOUS BEST OF BEAUTY BREAKTHROUGH AWARD

16-09-2025
FIRST FDA-APPROVED MEDICATION FOR ATOPIC DERMATITIS (ECZEMA), PLAQUE PSORIASIS, AND SEBORRHEIC DERMA...
Více zde

ARCUTIS BIOTHERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

05-09-2025
WESTLAKE VILLAGE, CALIF., SEPT. 05, 2025 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC.  (NASDAQ...
Více zde

ARCUTIS SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION FOR ZORYVE® (ROFLUMILAST) CREAM 0.3% TO EXPAND INDICATION FOR TREATMENT OF PLAQUE PSORIASIS IN CHILDREN AGES 2 TO 5

03-09-2025
IF APPROVED, ZORYVE CREAM WOULD BE THE FIRST AND ONLY TOPICAL PDE4 INHIBITOR INDICATED FOR PLAQUE PS...
Více zde

ARCUTIS TO PRESENT AT UPCOMING INVESTOR CONFERENCES

19-08-2025
WESTLAKE VILLAGE, CALIF., AUG. 19, 2025 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ...
Více zde

ARCUTIS BIOTHERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

08-08-2025
WESTLAKE VILLAGE, CALIF., AUG. 08, 2025 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC.  (NASDAQ:...
Více zde

ARCUTIS ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

06-08-2025
Q2 2025 NET PRODUCT REVENUE FOR ZORYVE® (ROFLUMILAST) WAS $81.5 MILLION, A 164% INCREASE COMPARED T...
Více zde

ARCUTIS TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON AUGUST 6, 2025

23-07-2025
ARCUTIS ANNOUNCED TODAY THAT IT WILL REPORT Q2 2025 FINANCIAL RESULTS AND PROVIDE A BUSINESS UPDATE ...
Více zde

ARCUTIS BIOTHERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

03-07-2025
WESTLAKE VILLAGE, CALIF., JULY 03, 2025 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ...
Více zde

ARCUTIS' ZORYVE® (ROFLUMILAST) CREAM 0.15% RECEIVES STRONG RECOMMENDATION IN AMERICAN ACADEMY OF DERMATOLOGY UPDATED GUIDELINES FOR ADULT ATOPIC DERMATITIS

26-06-2025
THE AMERICAN ACADEMY OF DERMATOLOGY (AAD) PROVIDED EVIDENCE-BASED RECOMMENDATION FOR THE USE OF ZORY...
Více zde

ARCUTIS ENROLLS FIRST CHILD IN INTEGUMENT-INFANT EVALUATING ZORYVE® (ROFLUMILAST) CREAM 0.05% IN INFANTS WITH ATOPIC DERMATITIS

10-06-2025
FOUR-WEEK PHASE 2 STUDY TO EVALUATE INVESTIGATIONAL, ONCE-DAILY ZORYVE .05% IN INFANTS AS YOUNG AS 3...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2025-12-08 00:00:008-KStáhnout
2025-10-28 00:00:008-KStáhnout
2025-10-28 00:00:0010-QStáhnout
2025-08-06 01:00:008-KStáhnout
2025-08-06 01:00:0010-QStáhnout
2025-08-06 00:00:008-KStáhnout
2025-08-06 00:00:0010-QStáhnout
2025-06-17 01:00:008-KStáhnout
2025-06-17 00:00:008-KStáhnout
2025-05-06 01:00:008-KStáhnout
2025-05-06 01:00:0010-QStáhnout
2025-05-06 00:00:008-KStáhnout
2025-05-06 00:00:0010-QStáhnout
2025-04-10 01:00:008-KStáhnout
2025-04-10 00:00:008-KStáhnout
2025-02-25 00:00:008-KStáhnout
2025-02-25 00:00:0010-KStáhnout
2025-02-24 23:00:008-KStáhnout
2025-02-24 23:00:0010-KStáhnout
2025-01-13 00:00:008-KStáhnout
2025-01-12 23:00:008-KStáhnout
2024-11-06 00:00:008-KStáhnout
2024-11-06 00:00:0010-QStáhnout
2024-11-05 23:00:008-KStáhnout
2024-11-05 23:00:0010-QStáhnout
2024-08-14 01:00:008-KStáhnout
2024-08-14 01:00:0010-QStáhnout
2024-08-14 00:00:008-KStáhnout
2024-08-14 00:00:0010-QStáhnout
2024-06-18 01:00:008-KStáhnout
2024-06-18 00:00:008-KStáhnout
2024-05-14 01:00:008-KStáhnout
2024-05-14 01:00:0010-QStáhnout
2024-05-14 00:00:008-KStáhnout
2024-05-14 00:00:0010-QStáhnout
2024-04-10 01:00:008-KStáhnout
2024-04-10 00:00:008-KStáhnout
2024-03-04 00:00:008-KStáhnout
2024-03-03 23:00:008-KStáhnout
2024-02-28 00:00:008-KStáhnout
2024-02-27 23:00:008-KStáhnout
2024-02-27 00:00:008-KStáhnout
2024-02-27 00:00:0010-KStáhnout
2024-02-26 23:00:008-KStáhnout
2024-02-26 23:00:0010-KStáhnout
2024-02-15 00:00:008-KStáhnout
2024-02-14 23:00:008-KStáhnout
2024-01-11 00:00:008-KStáhnout
2024-01-10 23:00:008-KStáhnout
2023-12-18 00:00:008-KStáhnout
2023-12-17 23:00:008-KStáhnout
2023-11-03 00:00:008-KStáhnout
2023-11-03 00:00:0010-QStáhnout
2023-11-02 23:00:008-KStáhnout
2023-11-02 23:00:0010-QStáhnout
2023-10-23 01:00:008-KStáhnout
2023-10-23 00:00:008-KStáhnout
2023-10-19 01:00:008-KStáhnout
2023-10-19 00:00:008-KStáhnout
2023-09-27 01:00:008-KStáhnout
2023-09-27 00:00:008-KStáhnout
2023-08-18 01:00:008-KStáhnout
2023-08-18 00:00:008-KStáhnout
2023-08-14 01:00:008-KStáhnout
2023-08-14 00:00:008-KStáhnout
2023-08-08 01:00:008-KStáhnout
2023-08-08 01:00:0010-QStáhnout
2023-08-08 00:00:008-KStáhnout
2023-08-08 00:00:0010-QStáhnout
2023-06-05 01:00:008-KStáhnout
2023-06-05 00:00:008-KStáhnout
2023-05-24 01:00:008-KStáhnout
2023-05-24 00:00:008-KStáhnout
2023-05-09 01:00:008-KStáhnout
2023-05-09 01:00:0010-QStáhnout
2023-05-09 00:00:008-KStáhnout
2023-05-09 00:00:0010-QStáhnout
2023-02-28 00:00:008-KStáhnout
2023-02-28 00:00:0010-KStáhnout
2023-02-27 23:00:008-KStáhnout
2023-02-27 23:00:0010-KStáhnout
2022-12-16 00:00:008-KStáhnout
2022-12-15 23:00:008-KStáhnout
2022-11-08 00:00:008-KStáhnout
2022-11-08 00:00:0010-QStáhnout
2022-11-07 23:00:008-KStáhnout
2022-11-07 23:00:0010-QStáhnout
2022-09-07 01:00:008-KStáhnout
2022-09-07 00:00:008-KStáhnout
2022-09-06 01:00:008-KStáhnout
2022-09-06 00:00:008-KStáhnout
2022-08-05 01:00:008-KStáhnout
2022-08-05 00:00:008-KStáhnout
2022-08-04 01:00:008-KStáhnout
2022-08-04 01:00:0010-QStáhnout
2022-08-04 00:00:008-KStáhnout
2022-08-04 00:00:0010-QStáhnout
2022-08-02 01:00:008-KStáhnout
2022-08-02 00:00:008-KStáhnout
2022-06-09 01:00:008-KStáhnout
2022-06-09 00:00:008-KStáhnout
2022-06-02 01:00:008-KStáhnout
2022-06-02 00:00:008-KStáhnout
2022-05-05 01:00:008-KStáhnout
2022-05-05 01:00:0010-QStáhnout
2022-05-05 00:00:008-KStáhnout
2022-05-05 00:00:0010-QStáhnout
2022-02-22 00:00:008-KStáhnout
2022-02-22 00:00:0010-KStáhnout
2022-02-21 23:00:008-KStáhnout
2022-02-21 23:00:0010-KStáhnout
2021-12-23 00:00:008-KStáhnout
2021-12-22 23:00:008-KStáhnout
2021-11-04 00:00:008-KStáhnout
2021-11-04 00:00:0010-QStáhnout
2021-11-03 23:00:008-KStáhnout
2021-11-03 23:00:0010-QStáhnout
2021-10-04 01:00:008-KStáhnout
2021-10-04 00:00:008-KStáhnout
2021-09-28 01:00:008-KStáhnout
2021-09-28 00:00:008-KStáhnout
2021-09-07 01:00:008-KStáhnout
2021-09-07 00:00:008-KStáhnout
2021-08-05 01:00:008-KStáhnout
2021-08-05 01:00:0010-QStáhnout
2021-08-05 00:00:008-KStáhnout
2021-08-05 00:00:0010-QStáhnout
2021-06-14 01:00:008-KStáhnout
2021-06-14 00:00:008-KStáhnout
2021-05-06 01:00:0010-QStáhnout
2021-05-06 00:00:0010-QStáhnout
2021-05-04 01:00:008-KStáhnout
2021-05-04 00:00:008-KStáhnout
2021-03-26 00:00:008-KStáhnout
2021-03-25 23:00:008-KStáhnout
2021-02-16 00:00:008-KStáhnout
2021-02-16 00:00:0010-KStáhnout
2021-02-15 23:00:008-KStáhnout
2021-02-15 23:00:0010-KStáhnout
2021-02-05 00:00:008-KStáhnout
2021-02-04 23:00:008-KStáhnout
2021-02-01 00:00:008-KStáhnout
2021-01-31 23:00:008-KStáhnout
2021-01-15 00:00:008-KStáhnout
2021-01-14 23:00:008-KStáhnout
2020-11-23 00:00:008-KStáhnout
2020-11-22 23:00:008-KStáhnout
2020-11-05 00:00:008-KStáhnout
2020-11-05 00:00:0010-QStáhnout
2020-11-04 23:00:008-KStáhnout
2020-11-04 23:00:0010-QStáhnout
2020-11-04 00:00:008-KStáhnout
2020-11-03 23:00:008-KStáhnout
2020-10-06 01:00:008-KStáhnout
2020-10-06 00:00:008-KStáhnout
2020-09-29 01:00:008-KStáhnout
2020-09-29 00:00:008-KStáhnout
2020-09-18 01:00:008-KStáhnout
2020-09-18 00:00:008-KStáhnout
2020-09-09 01:00:008-KStáhnout
2020-09-09 00:00:008-KStáhnout
2020-08-11 01:00:008-KStáhnout
2020-08-11 01:00:0010-QStáhnout
2020-08-11 00:00:008-KStáhnout
2020-08-11 00:00:0010-QStáhnout
2020-07-31 01:00:008-KStáhnout
2020-07-31 00:00:008-KStáhnout
2020-07-29 01:00:008-KStáhnout
2020-07-29 00:00:008-KStáhnout
2020-05-13 01:00:008-KStáhnout
2020-05-13 00:00:008-KStáhnout
2020-05-12 01:00:0010-QStáhnout
2020-05-12 00:00:0010-QStáhnout
2020-04-29 01:00:008-KStáhnout
2020-04-29 00:00:008-KStáhnout
2020-04-27 01:00:008-KStáhnout
2020-04-27 00:00:008-KStáhnout
2020-03-19 00:00:0010-KStáhnout
2020-03-18 23:00:0010-KStáhnout
preloader